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Abstract: Background: Fluvoxamine, an antidepressant drug, has absolute bioavailability of only 53% 
due to high first pass metabolism. Aim: The purpose of this study was to develop and optimize 
mucoadhesive microemulsion containing Fluvoxamine for intranasal delivery. Materials and Methods: 
Based on solubility study, Acrysol K150, Tween 20 and polyethylene glycol (PEG) 400 were selected as 
oil, surfactant and co surfactant respectively. Microemulsions were prepared using water titration 
method. 2:1% w/w ratio (Tween 20:PEG 400) was selected for formulation development. The prepared 
microemulsions were optimized for globule size, zeta potential, pH, Viscosity and polydispersity index. 
The optimized batch was further characterized for% drug content, pH, viscosity and % drug diffusion. 
Results and Conclusion: All the parameters showed the suitability of microemulsion of Fluvoxamine for 
intranasal delivery. Carbapol 934P (0.3 % w/w) was used as a polymer for the preparation of 
mucoadhesive microemulsion to enhance the retention time in the nasal mucosa. Results of nasal 
toxicity study using excised sheep nasal mucosa showed comparatively no damage to epithelium and so 
formulation was considered safe for nasal administration. Fluvoxamine mucoadhesive microemulsion 
showed the highest percentage of diffusion (98.07 ± 0.710 %) after 24h during ex-vivo drug diffusion 
study through sheep nasal mucosa, followed by Fluvoxamine microemulsion (93.48 ± 0.674%) and 
finally by Fluvoxamine solution (70.57 ± 0.612%). 
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INTRODUCTION 
Depression is the growing problems in many nations of the world. Depression is a state of low 
mood and aversion to activity that can affect a person’s thoughts, behavior, feelings and 
physical well being. All over the world there are 40 crore patients living with depression 
indicating its global prevalence. It impacts all aspects of everyday life including eating, sleeping, 
working, relationships, and how a person thinks about himself/herself. People who are clinically 
depressed cannot simply will themselves to feel better or just “snap out of it”. If they do not 
receive appropriate treatment their symptoms can continue for weeks, months, or years. 
The treatment of central nervous system (CNS) disorders is challenging because of a variety of 
formidable obstacles for effective and persistent delivery of drugs. Even though the drugs used 
for the treatment of CNS disorders are potent, their clinical failure is often not due to lack of 
drug efficacy but mainly due to shortcomings in the drug delivery approach. However, potent 
the drug may be, but if it cannot cross the blood brain barrier and reach the CNS in order to 
elicit its pharmacological action, it is ineffective.[1,2] Hence, to overcome the large number of 
barriers restricting the CNS drug delivery scientists are exploring the novel approaches so that 
delivery of the drugs can be enhanced and/or restricted to the brain and CNS. Various delivery 
strategies have been developed. Figure 1 briefly shows the various ways in which drug delivery 
to the brain has been tried. Out of all the strategies that have been listed, they can be 
categorized as invasive, noninvasive and miscellaneous techniques. Nasal drug delivery falls in 
the category of miscellaneous type. Current work is mainly focused on nasal to brain drug 
delivery so emphasis will be on nasal delivery in the following sections. 
 
Figure 1: Various approaches for CNS drug delivery [3] 
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Intranasal drug delivery is one of the focused delivery options for brain targeting as brain and 
nose compartments are connected to each other through olfactory/trigeminal route via 
peripheral circulation.[4]  Intranasal administration delivers drug directly to the brain 
circumventing the blood brain barrier and reduces drug distribution to the non targeted 
sites.[5,6]  This may result in reduction in dose, systemic dilution and first pass metabolism of the 
drug.[7] Nasal delivery route is convenient, patient friendly and also prevents the risk of the 
gastrointestinal tract irritation.[8] Direct nose to brain transport results in rapid and/or higher 
uptake in the brain, which proves to be an alternative option of self-medication in the 
management of emergencies.[4] 
Conventionally drugs were administered through intranasal route in the form of solutions, 
suspensions, gels, emulsions, powders etc. Such conventional dosage forms are having some 
disadvantages such as lack of dose precision, high particle size, high viscosity, lack of drug 
stability, solubility problem due to lipophilicity of drug etc. Some novel formulations such as 
microspheres, nanoparticles are also explored as drug delivery system for intranasal delivery.[9] 
However, their toxicity/irritancy on the nasal mucosa cells due to the presence of a variety of 
polymers/excipients is a major concern. Microemulsion is one such novel formulation which is 
optically isotropic and thermodynamically stable system composed of oil, water, surfactant 
(and/or co surfactant).[10]  Microemulsions offer several advantages like high solubilization of 
lipophilic drugs, stability, ease of preparation and stabilization of hydrolytically susceptible 
compounds. Microemulsions provide a large surface area for better absorption of drugs due to 
smaller globule size. Various drugs such as Sumatriptan,[11]  Zolmitriptan,[12] Cabergoline,[13]  
Clonazepam,[14]  Nimodipine,[15]  Tacrine,[16] and Diazepam[17]  have been successfully delivered 
through nasal route in the form of microemulsion and it resulted in improved drug absorption. 
In order to formulate a nasal formulation with desirable performance, it is advisable to focus on 
maximizing the residence time in the nasal mucosa and thus ensuring efficient absorption of 
drug.[18] Use of mucoadhesive polymers in the nasal formulations is expected to increase the 
residence time and thereby enhance the absorption of the drug. 
Fluvoxamine is an antidepressant drug used for the treatment of moderate to severe 
depression. Fluvoxamine is a potent and selective serotonin reuptake inhibitor with around 
100-fold affinity for the serotonin transporter over the norepinephrine transporter.[19] It has 
negligible affinity for the dopamine transporter or any other receptor, with the sole exception 
of the σ1 receptor.
[20] It behaves as a potent agonist at this receptor and has the highest affinity 
of any SSRI for doing so.[20] This may contribute to its antidepressant and anxiolytic effects and 
may also afford it some efficacy in treating the cognitive symptoms of depression. 
Fluvoxamine's only FDA approved indication is in the treatment of OCD,[21] although in other 
countries (e.g. Australia,[22] UK[23] and Russian Federation[24]) it has indications for MDD, as well. 
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Fluvoxamine has been found to be useful in the treatment of MDD, and anxiety disorders such 
as panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and obsessive-
compulsive spectrum disorders. Fluvoxamine is indicated for children and adolescents with 
OCD.[25] The drug works long-term, and retains its therapeutic efficacy for at least a year.[26] It 
has also been found to possess some analgesic properties in line with other SSRIs and tricyclic 
antidepressants.[27][28][29] Some evidence shows fluvoxamine may be a helpful adjunct in the 
treatment of schizophrenia, improving the depressive, negative, and cognitive symptoms of the 
disorder.[30] Its actions at the sigma receptor may afford it a unique advantage among 
antidepressants in treating the cognitive symptoms of schizophrenia.[31] 
In the light of the above facts, an alternative drug delivery system is needed, which can 
selectively target the candidate drug to the brain. Due to preferential transport of the drug to 
the brain, intranasal delivery approach may be expected to reduce the wide distribution of the 
drug to the non-targeted sites such as systemic/peripheral circulation. The delivery system 
must be meticulously designed to provide rapid transport of the drug across nasal mucosa and 
longer residence time in the nasal cavity. The aim of this investigation was to deliver 
Fluvoxamine in the form of mucoadhesive microemulsion through nasal route for the effective 
treatment of CNS disorders like anxiety and depression. The research work was carried out with 
objectives in mind to provide rapid drug delivery to the brain, to reduce side effects, maximize 
therapeutic index and to reduce the dose and dosing frequency. 
MATERIALS AND METHODS 
Materials 
Fluvoxamine was gifted by Torrent Pharmaceutical Limited, Ahmedabad, India. Corel Chemicals, 
Ahmedabad, India, gifted Acrysol K150. Tween 20 was purchased from the SD fine chemicals 
Limited, Mumbai, India. Polyethylene glycol (PEG) 400 was purchased from Himedia Private 
Limited, Mumbai, India. Carbopol 934P was gifted by Lubrizol, Ohio, USA. Other chemicals were 
of analytical grade andpurchased from SD Fine chemicals Limited, Mumbai, India. 
Methods 
Solubility determination 
Solubility of Fluvoxamine was determined in various oils, surfactants and cosurfactants. Drug 
was added in excess to different oils, surfactants and co surfactants and shaken using 
mechanical shaker for 48 h. The samples were then centrifuged at 6000 revolutions per minute 
(RPM) for 15 min and the drug content in the supernatant was analyzed using ultraviolet (UV) 
spectrophotometric method at λ max of 254 nm after suitable dilution with methanol. 
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Selection of Surfactant and Co-Surfactant 
300 mg of the surfactants was added to 300 mg of the selected oily phase. The mixtures were 
gently heated at 50°C for the homogenization of the components. Each mixture, 50 mg, was 
then diluted with distilled water to 50 mL in a stoppered conical flask. Ease of emulsification 
was judged by the number of flask inversions required to yield a homogenous emulsion. 
Emulsions were allowed to stand for 2 h and their % Transparency was evaluated at 650 nm by 
a double-beam UV-visible spectrophotometer using distilled water as a blank. The screening of 
the co-surfactant was conducted on the basis of % Transparency and ease of emulsification. 
Mixtures of 100 mg of the co-surfactant, 200 mg of the selected surfactant, and 300 mg of the 
selected oil were prepared and evaluated in a similar fashion as described in the above section 
on surfactant. 
Construction of the phase diagram 
The phase diagrams with different ratios of surfactant: Co-surfactant (1:1, 2:1, 3:1 % w/w) with 
selected oil was constructed to explore the microemulsion region. The area of the monophasic 
region was used as a tool for the selection of suitable surfactant and co surfactant mixture. 
Aliquots of each surfactant and co surfactant mixture (Smix) were mixed with oil at ambient 
temperature. For each phase diagram, the ratio of oil to the Smix was varied as 9:1, 8:2, 7:3, 
6:4, 5:5, 4:6, 3:7, 2:8, 1:9 (%w/w). Water was addeddrop wise to each oil-Smix mixture under 
constant stirring.After equilibrium, the samples were visually checked anddetermined as being 
clear microemulsions. Phase diagramswere constructed using SIGMA PLOT Software. 
Preparation of microemulsion 
Based on the phase diagram, the optimum Smix ratio was selected and the drug loaded 
microemulsions were prepared by dissolving the drug in the oil-Smix mixture, then titrated with 
water on the magnetic stirrer at 150 RPM for 10 min. 
Optimization of parameters 
Different batches of microemulsions were prepared by water titration method. Seven batches 
(F1-F7) were evaluated for Viscosity, pH, globule size, polydispersity index (PDI), % Drug 
Content and in-vitro Diffusion study. Optimized batch was selected on the basis of lower 
globule size and PDI and higher % Drug Diffusion.[32] 
Screening of mucoadhesive agent 
Mucoadhesive agents help to retain the formulation at site of administrationand prevent 
mucociliary clearance. Various polymers such as HPMC, Carbopol, and Chitosan in various 
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concentrations were evaluated formucoadhesion. For the study, dispersions of various 
concentrations ofmucoadhesive polymers were prepared by soaking them in water at 
roomtemperature for overnight and visually observed for their ability to form a film.After 
screening the polymers based on their gelling ability, they were incorporated in ME along with 
aqueous phase to form MME. The MME formed was further screened for globule size, zeta 
potential and Viscosity . Basedon these results the mucoadhesive polymer with specific 
concentration was finalized. 
Preparation of mucoadhesive microemulsion 
The mucoadhesive microemulsions were prepared by first preparing a microemulsion of the 
drug using minimum volume of external phase and then adding required volume of carbopol 
934P solution such that the final concentration of carbopol 934P was 0.3 % w/w in the 
formulation. 
Characterization of microemulsion 
Globule size determination 
Formulations (F1 to F7) each of 1 ml was diluted with 100 ml of water in a volumetric flask. The 
volumetric flask was inverted twice to ensure complete dispersion of the formulation. After 
ensuring complete dispersion of the formulation the droplet size of resultant microemulsion 
was determine by Zetasizer Nano Series (Malvern Instruments, UK). Light scattering was 
monitor at 25°C at 90° angle. 
pH 
A 10% dispersion of the formulation was prepared in distilled water and pH was determined by 
using  pH meter standardize with standard buffers of pH 4 and pH 7.4. 
Zeta potential determination 
Zeta potential of the formulation was measured by using Malvern Zetasizer (Malvern 
Instruments, UK). Zeta sizer measures the potential ranges from -120 to +120 V. For 
measurement of zeta potential 2 gm of formulation was diluted with milliQ water (100 ml). Zeta 
potential is essentially useful for assessing flocculation since electrical charges on particles 
influence the rate of flocculation. 
% Drug Content 
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Microemulsion formulation was analyzed for drug content by U.V. spectrophotometer 
(Shimadzu, UV1800) at 254 nm by taking 1ml of microemulsion and diluted with methanol 
appropriately. Experiment was performed in triplicate for each sample. 
In-vitro drug permeation study 
In order to estimate the amount of drug permeated in given time period, in-vitro permeation 
study through dialysis membrane was performed for the formulated Microemulsion system. In-
vitro permeation study was performed for drug loaded microemulsion. Dialysis membrane 
(cellulose membrane) was soaked in phosphate buffer (pH 6.4). The pre-soaked dialysis 
membrane was fixed between donor and receptor compartment of Franz diffusion cell (22 ml) 
and secured in position and thermo-stated at 37±0.5 oC using water bath, stirred magnetically 
at 400 rpm. The prepared formulations (1 ml) were applied on the donor side of the membrane. 
Samples were withdrawn from the receptor fluid at predetermined time intervals up to 24 
hours and replaced by equivalent amount of temperature equilibrated buffer. After appropriate 
dilution the sample was analyzed by UV-Vis spectrophotometer using phosphate buffer 6.4 as 
blank at 254 nm. The drug release was compared for the different formulations. 
Ex-vivo drug permeation study 
The freshly excised sheep nasal mucosa, except the septum part was collected from a local 
slaughter house. The superior nasal membrane was identified and separated from the nasal 
cavity and made free from adhered tissues. Maintaining the viability of the excised nasal tissue 
during the experimental period is important. Therefore the mucosa was carefully removed 
within 20 min of sacrificing the animal, and immediately immersed in ice cold phosphate buffer 
saline pH 6.4 and aerated. Ex-vivo permeation study was carried out using Franz Diffusion Cell 
(22 ml). The receptor compartment was filled with 22 ml of simulated nasal fluid and stirred 
magnetically at 400 rpm. The receptor compartment was maintained at 37±0.5 oC throughout 
the study period. Mucosal preparation was mounted on receptor compartment of Franz 
Diffusion cell having a permeation area of 2cm2 with the mucosal side facing the donor 
compartment and secured using a clamp, taking care to avoid entrapment of air bubble 
beneath the membrane. The tissue sample was allowed an incubation period of 15 min to 
attain 37 oC. The formulations (1 ml ) were uniformly spread over the mucosal surface after the 
incubation period. Permeation study was performed for a period of 24 hours. At predetermined 
time intervals, 1 ml of aliquot was withdrawn and replaced with thermo-stated receptor 
medium. The aliquots were diluted suitably using simulated nasal fluid and drug content 
determined using UV-vis spectrophotometric method. Amount of drug permeated was 
calculated from the calibration curve and compared for different formulations. 
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Histopathology studies 
Nasal mucosa of the animals without any dosing, animals dosed with Fluvoxamine 
Mucoadhesive Microemulsion system and one treated with isopropyl alcohol (control) were 
excisedand fixed in 10% formalin for histopathological studies.[33] Five micrometer sectioning of 
the nasal mucosa was done followed by staining with haemotoxylin and eosin. Microscopic 
examination was done for all possible anatomical changes. 
Results and Discussion 
Microemulsions are essentially clear systems and hence solubility of drug in all the components 
is necessary. It is necessary that the effective dose of the drug should be delivered within 
minimum volume of formulation. Hence, solubility study of Fluvoxamine was carried out in 
number of excipients that are generally regarded as safe (GRAS listed) for nasal administration. 
Based on solubility, Acrysol K 150 was selected as oil phase, Tween 20 as surfactant and PEG 
400 as cosurfactant as these components showed better solubility for Fluvoxamine. Results are 
tabulated in Table 1 and Figure 2. 
Table 1: Solubility Data of Fluvoxamine in Various Excipients 
Vehicle Function in Microemulsion Solubility (mg/ml)* 
Oleic acid Oil 33.84±0.262 
Acrysol K150 Oil 60.53±0.215 
Castor oil Oil 29.59±0.20 
IPM Oil 24.80±0.02 
Tween 80 Surfactant 11.75±0.055 
Tween 20 Surfactant 77.66±0.197 
Span 80 Surfactant 29.33±0.065 
Span 20 Surfactant 18.56±0.025 
Propylene glycol Co-Surfactant 11.56±0.052 
IPA Co-Surfactant 19.87±0.076 
PEG-400 Co-Surfactant 89.36±0.052 
Ethanol Co-Surfactant 51.55±0.0305 
*Values are mean ±SD (n=3) 
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Figure 2: Solubility study of Fluvoxamine in Various vehicles 
SELECTION OF SURFACTANT AND CO-SURFACTANT 
Non-ionic surfactants are generally considered less toxic than ionic surfactants. In this study, 
the two surfactants (Tween 80, Tween 20) were compared. The well-formulated microemulsion 
is dispersed within seconds under gentle stirring conditions, which ultimately depends on the 
emulsification ability of the surfactant. 
Results showed that the oily phase Acrysol K 150 exhibited the highest emulsification efficiency 
with Tween 20 [% Transparency: 98.58, 6 flask inversions] for the homogenous emulsion 
formation. On the other hand, Acrysol K 150 showed poor emulsification properties with other 
surfactant employed, requiring a higher number of flask inversions (as shown in Table 2). The 
results suggested the use of Acrysol K 150 as an oily phase with Tween 20 as a surfactant for 
further study. Addition of a co-surfactant to the surfactant-containing formulation was 
reported to improve dispersibility and drug absorption from the formulation. In the present 
investigation, two co-surfactants, namely, PEG-400 and ethanol were compared. As shown in 
Table 2 Acrysol K 150 exhibited good emulsification with all co-surfactants, with PEG-400 
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Table 2: %Transparency of various surfactants and Co-surfactants 
Surfactant/Co-surfactant % Transparency No. Of Inversion 
Tween 20 98.58 6 
Tween 80 97.19 14 
PEG-400 98.80 9 
Ethanol 96.75 17 
 
Pseudo ternary phase diagram 
In microemulsion system surfactant and co surfactant get preferentially adsorbed at the 
interface, reducing the interfacial energy as well as providing a mechanical barrier to 
coalescence. The selection of oil and surfactant and the mixing ratio of oil to S/CoS, play an 
important role in the formation of the microemulsion. This can be ascertained by pseudo 
ternary phase diagram as it differentiates the microemulsion region from that of 
macroemulsion region. By preparing phase diagram, microemulsion region can be obtained. 
Phase diagrams with different weight ratios of surfactant:Co surfactant (1:1, 2:1, 3:1 % w/w) 
were prepared and depending upon the microemulsion region the surfactant to co surfactant 
ratio was selected as 2:1 for further formulation development. The phase diagram is shown in 
Figure 3. 
 
Figure 3(a): Surfactant:Co-surfactant (1:1) 
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Figure 3(b): Surfactant:Co-surfactant (2:1) 
 
Figure 3(c): Surfactant:Co-surfactant (3:1) 
Preparation and optimization of microemulsion 
Numbers of batches (F1-F7) were prepared for the optimization of the microemulsion. The % oil 
and % S mix were varied and different batches were prepared. The prepared microemulsion 
batches were analyzed for globule size, PDI, pH, viscosity and % drug diffusion. The formulation, 
which had lesser globule size and PDI and higher % drug content and % drug diffusion from 
among all the batches, was selected as an optimum batch. The reason for selecting lower 
globule size was that it increases the permeation through the nasal mucosa as well as 
lowerglobule size can provide enhanced interfacial area for drug release and absorption. Lesser 
the PDI, more uniform the formulation is considered. In the same way, formulation with 
higher% drug diffusion as shown in Figure 4 and drug content was selected. The result of the all 
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the prepared batches is recorded in Table 3. From the Table, it shows that Microemulsion 
batch-5 (F5) was considered as optimized batch. It is having composition of 19 % Acrysol K150, 
33 % S mix and 48% water. Mucoadhesive microemulsion was prepared with the same 
composition having 0.3 % carbopol 934P as mucoadhesive polymer. The detailed composition 
of optimized batch of Microemulsion and mucoadhesive microemulsion is shown in Table 4. 
Table 3: Evaluation of microemulsion 
FORMULATION Globule 
size (nm) 




F1 71.91±0.24 0.328 6.4±0.215 63±0.002 83.45±0.213 99.72±0.12 
F2 42.48±0.21 0.510 6.5±0.045 75±0.20 86.08±0.334 98.67±0.57 
F3 53.21±0.23 0.494 6.2±0.180 71±0.005 84.83±0.392 98.46±0.36 
F4 37.25±0.18 0.268 6.2±0.138 77±0.10 89.15±0.523 99.02±0.18 
F5 29.21±0.24 0.262 6.5±0.005 68±0.004 93.48±0.674 99.87±0.21 
F6 39.92±0.21 0.369 6.7±0.230 66±0.140 87.95±0.588 99.37±0.59 
F7 34.80±0.23 0.307 6.6±0.197 75±0.006 91.73±0.219 99.42±0.34 
(*Values are mean ±SD (n=3)) 
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Table 4: Optimized batch of microemulsion and mucoadhesive microemulsion 
Components Quantity (% w/w) 
Microemulsion % Mucoadhesive microemulsion % 
Acrysol K150 18 % 18 % 
Tween 20 22 % 22 % 
PEG 400 10 % 10 % 
Water 50 % 49.7 % 
Carbopol 934P - 0.3 % 
 
Characterization of microemulsion 
The drug loaded microemulsion and mucoadhesive microemulsion were prepared and 
characterized for their pH, globule size as shown in Figure 5 and 6, zeta potential as shown in 
Figure 7 and 8, % drug content, % drug diffusion as shown in Figure 9 and the results are 
recorded in Table 5. 
For Optimized Microemulsion: 
   Size (d.nm): % Intensity Width (d.nm): 
Z-Average 
(d.nm): 
29.21 Peak 1: 21.41 61.0 7.631 
PDI: 0.262 Peak 2: 152.5 33.1 54.86 
Intercept: 0.952 Peak 3: 4554 6.0 849.8 
 
 
Figure 5: Globule Size of F5 (Optimized Microemulsion) 
Research Article                                   CODEN: IJPRNK                                         ISSN: 2277-8713                                                       
Hitarth Patadiya, IJPRBS, 2015; Volume 4(2): 472-491                                                  IJPRBS 
 
Available Online at www.ijprbs.com 
485 
For Mucoadhesive Microemulsion: 
   Size (d.nm): % Intensity Width (d.nm) 
Z-Average (d.nm): 35.92 Peak 1: 52.17 100.0 34.10 
PDI: 0.264 Peak 2: 0.000 0.0 0.000 
Intercept: 0.936 Peak 3: 0.000 0.0 0.000 
 
 
Figure 6: Globule Size of Mucoadhesive Microemulsion 
 
Figure 7: Zeta Potential for F5 (Optimized Microemulsion) 
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Figure 8: Zeta Potential for Mucoadhesive Microemulsion 
Table 5: Characterization of microemulsion 
Parameters Microemulsion (F5) Mucoadhesive microemulsion 
% Drug Content 99.87±0.21 99.52±0.33 
% Drug Diffusion 93.48±0.674 98.07 ± 0.710 
Globule Size 29.21±0.24 35.92±0.37 
PDI 0.262 0.264 
Zeta Potential -19.9 -17.9 
pH 6.5±0.005 6.2±0.046 
Viscosity 68±0.004 73±0.135 
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Histopathology studies 
The microscopic observations indicate that the prepared Mucoadhesive Microemulsion has no 
effect on integrity of cells of nasal mucosa when compared with the untreated nasal mucosal 
sample (Figure 10). As shown in Figure 11, neither necrosis nor removal of cells of epithelium 
were observed from the nasal mucosa under 40X magnification. However, in case of isopropyl 
alcohol treated sample of nasal mucosa disruption of cell integrity and damage of the epithelial 
layer was observed, as shown in Figure 12. Thus the formulation seems to be safe with respect 
to nasal irritation 
 
Figure 10: Histopathological section of intact (untreated) nasal mucosa 
 
Figure 11: Histopathological section of nasal mucosa treated with Fluvoxamine Mucoadhesive 
Microemulsion 
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Figure 12: Histopathological section of nasal mucosa treated with Isopropy alcohol 
CONCLUSION: 
Microemulsion of Fluvoxamine was prepared and optimized by using in-vitro parameters like 
particle size, PDI, zeta potential, pH, % drug diffusion, % drug content. Optimal microemulsion 
contains Acrysol K150 as oil phase, Tween 20 as a surfactant and PEG 400 as co surfactant. The 
% weight ratio of surfactant to co surfactant was selected as 2:1. The developed optimal 
microemulsion containing Fluvoxamine had globule size 29.21 nm, PDI 0.262, zeta potential − 
19.9 mV, % drug content 99.87±0.21 and % drug diffusion 93.48±0.674. Mucoadhesive 
microemulsion was also developed using 0.3% Carbopol 934P. Nasal toxicity study was carried 
out in an excised sheep nasal mucosa to evaluate the effect of microemulsion components on 
nasal mucosa and the results showed that prepared formulations were safer for nasal 
administration. Our study illustrated the potential use of microemulsion system to administer 
Fluvoxamine by nasal route. 
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